Niklas Klümper, Senior Urology Consultant at the University Medical Center Bonn, shared on X:
“Personalized cancer vaccines reach Phase III.
Very exciting topline results from INTerpath-001:
Intismeran autogene + pembrolizumab met both
- primary endpoint: RFS
- key secondary endpoint: DMFS
vs pembrolizumab alone after complete resection of stage IIB-IV melanoma.
Why this matters beyond melanoma:
Intismeran is an individualized mRNA neoantigen therapy, generated from the unique mutational profile of each patient’s tumor
This is the first positive Phase III readout for an individualized neoantigen therapy / mRNA-based cancer therapy.
The Phase II signal was already impressive and durable: at 5 years, adding intismeran reduced the risk of recurrence/death by 49% (HR 0.51) and distant metastasis/death by 59% (HR 0.41).
Now we need to see the full Phase III data: effect size, absolute benefit, safety, subgroups – and ultimately OS.
Particularly exciting from a precision-oncology perspective:
tumor sequencing – patient-specific neoantigens – individualized therapy – improved clinical outcome!
And highly relevant beyond melanoma, with the platform already being investigated across other tumors, including bladder cancer and RCC.”
“A potentially important milestone for truly individualized cancer immunotherapy.”
You can also read: Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma
